Randomised double blind controlled trial of cyclosporin in multiple sclerosis.
AUTOR(ES)
Rudge, P
RESUMO
In a 2 year double blind controlled trial of cyclosporin against placebo in multiple sclerosis conducted at two centres there was a beneficial effect of the therapy upon the progression of the disease, relapse rate and relapse severity at one of the centres where the patients received a mean dose of 7.2 mg/kg/day. This beneficial effect was not seen in the other centre where a lower dose (mean 5 mg/kg/day) was given. Reduction in clinical progression was accompanied by decreased IgG synthesis in the central nervous system. Side effects included hypertension, renal insufficiency and anaemia and were of such severity to preclude the use of cyclosporin in a high enough dose to alter the course of the disease.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1032160Documentos Relacionados
- Double-blind controlled trial of azathioprine in the treatment of multiple sclerosis.
- A double-blind controlled trial of high dose methyl prednisolone in multiple sclerosis.
- A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis.
- Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial
- A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis.
